Monte Rosa Therapeutics
A biotechnology company focused on developing molecular glue degraders (MGDs) to target undruggable or inadequately drugged targets.
Last updated September 1, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Monte Rosa Therapeutics is a biotechnology company that leverages expertise in molecular glue degrader (MGD) chemistry, artificial intelligence (AI), structural biology, and proteomics to advance MGD programs targeting undruggable or inadequately drugged targets with unprecedented specificity. The company has locations in Boston and Basel and is publicly traded under the ticker GLUE.
History
Monte Rosa Therapeutics was founded in April 2018 as Monte Rosa Therapeutics AG. In April 2021, the company moved to Summer St in Boston. In June 2021, it went public with the ticker GLUE. In August 2021, it moved to Klybeck in Basel. In November 2021, it declared its first development candidate, MRT-2359, a GSPT1 degrader. In October 2022, the first patient was dosed with MRT-2359. In May 2023, the company moved into a state-of-the-art lab in Boston's south end and declared its second development candidate, MRT-6160, a VAV1 degrader. In March 2024, it declared its third development candidate, MRT-8102, a NEK7-directed MGD.
Sources2 sources
Cite this profile: Cite the canonical profile. /brand-wiki/monte-rosa-therapeutics · Editorial policy · How profiles are compiled